FCM
BLTE

Farallon Capital Management’s Belite Bio BLTE Stock Holding History

Farallon Capital Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,300
Closed -$207K – 102
2026
Q1 		$207K Buy
+1,300
New +$219K ﹤0.01% 143

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Farallon Capital Management's BLTE Position: Q2 2026 in Review

Farallon Capital Management sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 1,300 shares — an estimated $207K sold.

Farallon Capital Management first reported a position in BLTE in Q1 2026 and held it in 1 quarter. The position peaked at $207K in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Farallon Capital Management reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
  • Farallon Capital Management sold 1,300 Belite Bio shares in Q2 2026, an estimated $207K.
  • Farallon Capital Management first reported a position in Belite Bio in Q1 2026 and held it in 1 quarter.
  • Farallon Capital Management's Belite Bio position peaked at $207K in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.